DVA vs GH: fair value comparison
DaVita Inc. and Guardant Health, Inc. · Updated 2026-10-19
GH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DVA currently ranks higher by quality score.
| DVA | GH | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $179.25 | $158.60 |
| 12-month range | $103.87–$240.96 | $69.35–$187.22 |
| Rank by discount to fair value | #29 of 108 Healthcare | — |
| Rank by quality score | #100 of 301 Healthcare | #101 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: DVA fair value analysis · GH fair value analysis